Skip to main content

Table 1 Baseline characteristics

From: An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

Variables

 

Age (years)

70.0 (63.8, 72.8)

Male (%)

9 (81.8)

Diabetes duration (years)

25.5 (22.0, 30.3)

Hemodialysis duration (years)

4.3 (2.8, 5.2)

Oral anti-diabetic agents

 

 α-glucosidase inhibitor (%)

1 (8.3)

Primary disease of ESKD

 

 Diabetic nephropathy (%)

11 (91.7)

 MPO-ANCA associated vasculitis (%)

1 (8.3)

  1. Data are expressed as median (interquartile range) or n (%)
  2. ESKD, end-stage kidney disease